gastrointestinal activity in myxoedema-from chronic constipation to the most severe ileus-has been reported. The milder forms are reversible with thyroid hormone replacement, but more severely affected patients die of other complications of hypothyroidism before treatment has had time to be effective. Only one other report² has attributed death to the ileus.

The pathological findings in our case suggest that the ileus was due to a peripheral neuropathy affecting the gut. Myxoedema is known to be associated with a polyneuropathy,³ the changes in peripheral nerves suggesting that Schwann cell disease, possibly caused by mucopolysaccharide deposition, is partly or wholly responsible for the disorder. Although no mucopolysacchardie was found in this case, Byrom⁴ showed that it disappears within days of thyroid hormone administration. The axons, however, were abnormal, showing a severe autonomic neuropathy affecting mainly the extrinsic nerves in the colon, but also suggesting intrinsic nerve involvement.

That peripheral neuropathy can affect the alimentary canal as well as the limbs is well recognised, as in diabetes mellitus.⁵ Anatomical changes in bowel innervation are in fact common, but clinical symptoms are rare, probably because slight changes in the nerve supply to the limbs are enough to produce parasthesiae, but to produce a megacolon damage has to be almost complete. The pathological changes in this case suggest that the ileus might have been reversible with thyroid hormone replacement had the patient survived.

¹ Bastenie, P A, Lancet, 1946, 1, 413.

² Chadha, J S, Ashby, D W, and Cowan, W K, British Medical Journal, 1969. 3. 398.

³ Dyck, P J, and Lambert, E H, Journal of Neuropathology and Experimental Neurology, 1970, 29, 631.

Byrom, F B, Clinical Science, 1933-34, 1, 273.

⁵ Smith, B, Journal of Neurology, Neurosurgery, and Psychiatry, 1974, 37, 1151.

(Accepted 19 October 1976)

Department of Diagnostic Radiology, King's College Hospital, London SE5

IRVING WELLS, MB, MRCP, registrar

Department of Pathology, St Bartholomew's Hospital, London EC1 BARBARA SMITH, MD, FRCS, senior lecturer

St Richard's Hospital, Chichester, Sussex

MICHAEL HINTON, BM, MRCP, consultant physician

Klinefelter's syndrome with hypogonadotrophic hypogonadism

Patients with Klinefelter's syndrome have raised circulating follicle stimulating hormone (FSH) levels. Luteinising hormone (LH) levels are usually increased also, but they may be within the normal range when the testosterone secretion rate approaches normal.¹ We describe here a patient who showed the clinical features of Klinefelter's syndrome associated with low testosterone levels, undetectable LH, and FSH levels that were not raised. When the patient's age is considered the FSH levels were actually below normal.²

Case report

A 70-year-old man with an eight-year history of diabetes mellitus presented with gangrene of the left foot. Conservative treatment was unsuccessful and

Responses to LHRH test (100 µg given intravenously)

a below-knee amputation was subsequently performed. On examination he was mildy obese and appeared hypogonadal with a high-pitched voice, a eunuchoidal habitus (span 187 cm, height 174 cm, and upper lower segment ratio of 0.8:1), smooth skin, and fine, soft, facial hair. There was bilateral $(2 \times 2 \text{ cm})$ gynaecomastia, body hair was sparse, both testes were soft $(1 \times 0.5 \text{ cm})$, and his penis was 5 cm in length (stretched). Visual fields and sense of smell were unimpaired. There were signs of peripheral vascular disease in the right leg but no carotid bruits were present. The fundi were not seen owing to bilateral cataracts. On direct questioning he said that he had developed only a small amount of pubic and axillary hair in his teenage years and that he had never shaved. There was no family history of endocrinopathy.

A clinical diagnosis of Klinefelter's syndrome was confirmed by a positive buccal smear and a karyotype of 47,XXY from peripheral blood. The serum testosterone level was 1.04 nmol/l (0.29 ng/ml), serum LH $<25 \mu g$ LER-907/1, and serum FSH 230 μ g LER-907/1. A luteinising hormone-releasing hormone (LHRH) test showed normal FSH and LH responses (see table). A thyrotrophin-releasing hormone test (400 μ g intravenously) resulted in normal thyrotrophin and prolactin responses. Serum cortisol was 640 nmol/l (23·2 µg/100 ml) (normal 200-660 nmol/l (7·0-23·9 µg/100 ml)). Radiographs of the sella turcica were normal, as was a brain scan.

No androgen replacement therapy was considered to be warranted, and after he recovered from the amputation the patient was discharged from hospital.

Comment

There are only two other reports describing patients with chromatinpositive Klinefelter's syndrome associated with low gonadotrophin levels. The first describes a 74-year-old man with XY/XXY mosaicism who had low circulating LH and testosterone levels. No comment was made about the FSH levels.3 The second report describes an 18-yearold man with XO/XY/XXY mosaicism in whom the circulating FSH levels were undetectable. Serum testosterone levels were in the low normal range and serum LH levels varied between normal and high values.4

The cause of the bihormonal gonadotrophin deficiency in our patient is obscure and a congenital abnormality cannot be excluded. A pituitary tumour seems unlikely in view of the normal skull radiographs, visual fields, and provocative test results. Diabetes mellitus, which presumably predisposed to the peripheral vascular disease, could theoretically have affected the microvasculature of the hypothalamicpituitary axis, but it is unlikely that this would have resulted in a 'selective'' gonadotrophin deficiency (although growth hormone reserve was not tested), particularly as the responses to LHRH were normal. Possibly our patient's condition represents a variant of Klinefelter's syndrome with a reduction in the release of LH and FSH occurring secondary to prolonged hypersecretion, as suggested by Rabinowitz et al in their case report mentioned above.⁴

INC is an overseas fellow of the Royal Australasian College of Physicians. The support of the Postgraduate Medical Foundation is gratefully acknowledged.

- ¹ Williams, R H (editor), Textbook of Endocrinology, 5th edn, p 335. Philadelphia, Saunders, 1974.
- ² Stearns, E L, et al, American Journal of Medicine, 1974, 57, 761. ³ Shirai, M, Matsuda, S, and Jitsukawa, S, Tohoku Journal of Experimental
- Medicine, 1974, 114, 131. ⁴ Rabinowitz, D, et al, American Journal of Medicine, 1975, 59, 584.

(Accepted 4 October 1976)

Section of Endocrinology and Metabolism, Department of Physiology, University of Manitoba, Winnipeg, Manitoba, Canada

- J N CARTER, MD, FRACP, fellow in endocrinology
- D G H WISEMAN, MD, FRCP(C), senior resident in endocrinology
- H B LEE, MD, senior resident in endocrinology

Time (min):	-30	0	15	30	45	60	90	120	180	Normal values*
FSH (μg LER-907/1) LH (μg LER-907/1) Testosterone (nmol/l)	230 <25 1·04	200 <25	310 53	380 79	430 101	470 119	510 170	670 190	870 210 0·73	$\begin{array}{r} 469 \pm 55 \\ 97 \pm 66 \\ 14 \cdot 4 \pm 6 \cdot 0 \end{array}$

*Normal basal values (±SD) for men aged 70-79 years.³. Conversion: SI to traditional units—Testosterone: 1 nmol/1≈0.288 ng/ml.